TOP: A Phase III, Multicentre, Randomized Controlled Study Comparing Osimertinib in Combination with Carboplatin and Pemetrexed to Osimertinib Monotherapy for Untreated Patients with Advanced Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) with Concurrent EGFR and TP53 Mutations.